$OSCR

Blackley Richard Scott sold $202K of OSCR

Blackley Richard Scott (Chief Financial Officer) sold 8,977 shares of Oscar Health, Inc. (OSCR) at $22.45 ($0.20M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blackley Richard Scott
Published Jun 4, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Neutral
medium confidence
Mentioned
$OSCR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRNeutralLow
01

Why it matters

The disclosed sale adds a datapoint on insider activity but does not, by itself, indicate a new corporate event like earnings, guidance, or a deal.

02

Market read

Traders may monitor insider activity, but 10b5-1 structure typically limits immediate fundamental inference.

03

What to watch

The filing doesn’t reveal the broader context (e.g., total planned sales, tax-related liquidity needs, or whether other insiders are buying).

Relevance 6/10Novelty 6/10Timing: After-hours/filing update (Form 4 filed 2026-06-04)

Background

This is an SEC Form 4 insider transaction disclosure for Oscar Health, reporting an officer’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$OSCRNeutralMedium confidence
Context

Oscar Health CFO sold 8,977 shares in an open-market transaction under a pre-arranged 10b5-1 plan, disclosed via SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely small and fades unless accompanied by other catalysts.

Evidence & confidence

The filing provides a specific sale datapoint (date, shares, price) but no accompanying fundamental change; 10b5-1 typically reduces interpretive weight.

Market effects

Minimal—single-company insider transaction with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with valuation concerns; traders may still fade rallies if selling cadence accelerates.

Key entities

  • Oscar Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Blackley Richard Scott

    Chief Financial Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OSCRHighAI 8/10

OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises

Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.

$OSCRHighAI 8/10

Oscar Health boosts 2026 earnings outlook, affirms revenue

Oscar Health (OSCR) updated its 2026 earnings outlook, lowering its Medical Loss Ratio to 81.0%-82.0% and raising earnings from operations to $600M-$800M. The company reaffirmed revenue guidance of $18.7B-$19.0B and maintained SG&A expense ratio targets. The updates will be discussed at its 2026 Investor Day on September 16, 2026.

$OSCRHighAI 8/10

Oscar Health raises FY26 earnings guidance by $100 million

Oscar Health (OSCR) raised its 2026 earnings guidance by $100 million, citing improved cost controls. The company expects earnings from operations to range from $600 million to $800 million, with a medical loss ratio of 81.0% to 82.0%. Total revenue guidance remains unchanged at $18.7 billion to $19.0 billion. The stock has gained 85.57% over the past year, reaching a 52-week high of $27.59.

$CNCMed

CNC, OSCR Stocks Rally After Baird Calls Risk Adjustment Results Favorable

Centene (CNC) and Oscar Health (OSCR) shares rose 6% and 12% respectively after Baird reported favorable risk adjustment results. Baird noted the outcomes support Centene's Q4 commentary and align with Oscar's June investor conference remarks. Molina (MOH) shares also rose 2% despite a minor negative impact. The Centers for Medicare & Medicaid Services released final 2025 risk adjustment data on June 30, affecting insurers' earnings.